and supported by, the phenotypic PCP features of Frizzled/PCP core group genes on one side and that of the Fat/ Dachsous system on the other. Flies carrying mutations in Frizzled/PCP core proteins exhibit defects in PCP throughout the wing. In contrast, the Fat/Dachsous system mainly affects polarity in the proximal half of the wing, as this area strongly depends on cellular realignment and rotation during the switch to the proximal-distal PCP axis. Together, these observations provide an exciting new framework for understanding the generation of PCP and its relation to new mechanisms that sculpt the shape of organs in general.
In a tour-de-force study, Kobayashi et al. (2010) describe the first viable rat-mouse chimeras and demonstrate that rat induced pluripotent stem (iPS) cells can rescue organ deficiency in mice. Rat iPS cells formed a fully functional pancreas when injected into mouse blastocysts lacking the Pdx1 gene required for pancreas formation.
Experimentally produced chimeras between different mouse strains (Tarkowski, 1961) have been an exceedingly useful tool for developmental biologists, contributing to our understanding of the establishment of cell lineages, cell determination, and the development of the immune system and other organs. In this issue of Cell, Kobayashi et al. (2010) dramatically extend the potential of mammalian chimeras with their report of viable rat-mouse chimeras that can develop to term and become fully functional adults.
In their study, Kobayashi and colleagues relied on previous knowledge but also added a few new wrinkles. They first derived mouse and rat embryonic stem (ES) cells and induced pluripotent stem (iPS) cells using standard methods for the mouse and capitalizing on the recent isolation of rat ES and iPS cells (Buehr et al., 2008; Li et al., 2008) . Both mouse and rat cells were tagged with different fluorescent dyes, allowing the authors to follow their distribution in the developing chimeras. The authors wanted to prove, at least in principle, that xenogeneic organ complementation could be achieved, that is, that donor cells of one species could rescue a defect in organ development in a recipient of a different species. So, as a first step, they set out to produce viable chimeras between rats and mice, even though many previous efforts to make such chimeras had failed. The only viable intergeneric chimerathat is, a hybrid between animals from different genera-reported so far is the geep between a sheep (Ovis aries) and a goat (Capra hircus) (Fehilly et al., 1984) .
To test the possibility that viable ratmouse chimeras could be formed, Kobayashi et al. (2010) injected fluorescently labeled mouse or rat iPS cells into rat or mouse blastocysts, respectively, and returned them to blastocyst-compatible pseudopregnant females (that is, foster mothers of the same species as the blastocysts). The authors then examined the resulting fetuses, newborns, and adults and found evidence of a substantial contribution of donor stem cells to tissues and organs of the host ( Figure 1A) . Despite a big contribution of donor cells, the size of newborn and adult chimeras (with one exception) was determined by the species of the host blastocyst. It is not clear whether it is the embryo itself or the uterine environment that determines the extent of chimera growth. To distinguish between these possibilities, one would have to transfer chimeric embryos into the uterus of pseudopregnant females of the same species as the donor stem cells (not the blastocysts). Previous studies suggest that such experiments would fail because of the need for compatibility between the fetal part of the placenta and the uterus (Rossant et al., 1982) .
Besides controlling the size and growth of the chimera, the host blastocyst seems to impose additional morphogenetic regulation. The postimplantation development of normal rat and mouse embryos is very similar, but there are differences in organ morphogenesis. One of the most noticeable differences is the presence of a gall bladder in mice and its absence in rats. In all adult chimeras produced by combining rat stem cells and mouse blastocysts, the resulting ''mouse-like'' chimeras had a gall bladder despite the significant contribution of rat cells to abdominal organs. Reciprocal chimeras were ''rat-like'' and, again, despite a significant contribution from mouse cells to abdominal organs, the gall bladder was absent. These results suggest that cells of the blastocyst inner cell mass possess a ''morphogenetic'' capacity that controls the behavior of injected stem cells at all developmental stages.
This may explain why Kobayashi et al. were able to successfully inject rat stem cells into mouse blastocysts, whereas insertion of the rat inner cell mass into the mouse blastocyst cavity did not result in viable rat-mouse chimeras (Gardner and Johnson, 1973) . This notion could be tested further using tetraploid complementation (that is, donor ES or iPS cells are injected into tetraploid blastocysts) to produce rat-mouse chimeras (Nagy et al., 1993) . Tetraploid blastocyst cells cannot participate in formation of the embryo proper; thus, the resulting fetus (and adult) is derived entirely from the injected cells, whereas the placenta and extraembryonic membranes are derived from the tetraploid blastocyst. It remains to be seen whether this approach could produce a fetus derived entirely from mouse ES cells after their injection into a rat tetraploid blastocyst that then develops in the uterus of a pseudopregnant rat female.
A major goal of the Kobayashi et al. study was to determine whether stem cells from a xenogeneic donor mammal could correct a genetic defect in a recipient mammal of a different species. So, in their next set of experiments, the authors injected rat iPS cells into recipient mouse blastocysts that lacked the Pdx1 gene, Figure 1 . Generating Rat-Mouse Chimeras (A) Induced pluripotent stem (iPS) cells were derived from adult mouse and rat cells and were labeled with different fluorescent proteins. Rat (blue) and mouse (red) iPS cells were injected into reciprocal blastocysts (mouse into rat and vice versa) to produce intergeneric chimeras. From these blastocysts, several chimeras were born and some survived to adulthood. The contribution of injected donor stem cells was observed throughout the body of the host. The size and morphology of the newborn and adult chimeras was determined by the host blastocyst. (B) Fluorescently labeled rat iPS cells (blue) were injected into normal mouse blastocysts (left) or blastocysts lacking the Pdx1 gene (right), which encodes the transcription factor pancreatic and duodenal homeobox 1 that is required for pancreas development. Chimeras derived from normal or Pdx1-deficient mouse blastocysts showed an extensive contribution of rat cells to all tissues. However, in the Pdx1-deficient chimeras, the entire pancreas was derived from donor rat cells (inset, blue) and was fully functional, including production of insulin by b islet cells.
which encodes a transcription factor (pancreatic and duodenal homeobox 1) that is essential for development of the pancreas and formation of insulinproducing b islet cells. Although they observed a substantial contribution of rat cells to different organs and tissues, most importantly, the pancreas of the rat-mouse chimeras was composed exclusively of rat cells ( Figure 1B) . Thus, cells derived from rat iPS cells were able to completely rescue the genetic deficiency of the host mouse blastocyst. These rat-mouse chimeras developed into adult animals with a normal functional pancreas, demonstrating that xenogeneic organ complementation is achievable. This is a remarkable accomplishment.
So where do we go from here? Although human ES and iPS cells offer hope for tissue and cell replacement therapies in the not too distant future, the replacement of complex organs-lung, kidney, liver, gut, and, of course, pancreas-is likely to be much more difficult. Several strategies for organ replacement are being tested. These include the growth of organs in vitro with mixtures of different stem cells and biocompatible scaffolds or the generation of ''humanized'' pigs engineered to lack certain antigens so that their organs can be used for transplantation in human patients with a reduced chance of immune rejection. Could production of human organs in, for example, human-pig chimeras be an alternative approach? Although production of viable rat-mouse chimeras could be viewed as a first step in this direction, as Kobayashi et al. propose, there are huge biological and technical challenges. For example, the mouse and rat are developmentally very similar (apart from size), but it is not clear that chimeras between animals belonging to different phylogenetic families or orders would be viable. Indeed, the only attempts to make such chimeras (between a mouse and a bank vole) have failed (Mystkowska, 1975) . In this experiment, the mouse-bank vole chimeras were made by aggregation of embryos; it is possible that injection of bank vole stem cells into mouse blastocysts, followed by their development in the uterus of mouse foster mothers might yield positive results. Successful chimerism between members of different orders (the pig and human, for example) seems very unlikely, and attempts to produce early postimplantation humanmouse chimeras have not been encouraging (James et al., 2006) . Even if we succeed in developing organ-deficient pigs by genetic manipulation and producing pig-human chimeras in which the parenchymal cells of the specific organ are entirely derived from human cells, immune rejection will still be a problem because the human organ carried by the pig will contain pig-derived stromal cells and blood vessels.
Finally, there are huge legal and ethical barriers to creating human-animal chimeras and, indeed, their production is forbidden in most countries. However, it is possible that injecting human ES or iPS cells into a mouse blastocyst and allowing limited (early postimplantation) development of human-mouse chimeras would be approved for the specific purpose of testing the differentiation potential of human stem cells. Yet such experiments will be complicated, time consuming, difficult to interpret, and, I suspect, will never become part of the standard protocols regulating the medical use of human stem cells. Although xenogeneic organ complementation is unlikely to be a viable strategy for regenerative medicine, the elegant work of Kobayashi et al. is a boon for researchers seeking to better understand the biology of stem cells and mammalian development.
